Vascular Control Systems
Stage
Acquired | AcquiredTotal Raised
$5.75MAbout Vascular Control Systems
Vascular Control Systems is a privately held company focused on developing medical devices to treat fibroids and to control bleeding in obstetric and gynecologic applications.
Missing: Vascular Control Systems's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vascular Control Systems's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Vascular Control Systems Patents
Vascular Control Systems has filed 9 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/19/2002 | 11/8/2011 | Surgical removal procedures, Gynaecology, Women's health, Gynecological surgery, Surgical oncology | Grant |
Application Date | 11/19/2002 |
|---|---|
Grant Date | 11/8/2011 |
Title | |
Related Topics | Surgical removal procedures, Gynaecology, Women's health, Gynecological surgery, Surgical oncology |
Status | Grant |
Latest Vascular Control Systems News
Aug 17, 2015
Tweet 5/9/2006 12:59:56 PM SOMERVILLE, N.J., May 9 /PRNewswire/ -- ETHICON, Inc. today announced it has acquired Vascular Control Systems, Inc. ( http://www.vascularcontrol.com ), a privately held company focused on developing medical devices to treat fibroids and to control bleeding in obstetric and gynecologic applications. Terms of the transaction were not disclosed. Uterine fibroids are a common women's health problem occurring in an estimated one-third of women over age 30. Fibroids, which are a leading indication for hysterectomy, can cause pelvic pain, heavy menstrual bleeding and infertility. The primary technology acquired by ETHICON is a uterine artery occlusion treatment that offers a minimally-invasive alternative to current therapies. "This represents a strong, strategic fit with our gynecologic business," said Sheri S. McCoy, company group chairman for Johnson & Johnson with responsibility for the ETHICON franchise. "The technology and knowledge we'll gain will enable us to expand our ability to create new therapies for women. " ETHICON, a Johnson & Johnson company, is a global medical device company that develops and markets surgical products for use in general surgery, wound management, women's health and cardiovascular surgery. Headquartered in Somerville, New Jersey, ETHICON conducts business in 52 countries and employs approximately 9,000 employees in its various worldwide locations. For information about ETHICON and its products, visit http://www.ethicon.com . ETHICON, Inc.
Vascular Control Systems Frequently Asked Questions (FAQ)
Where is Vascular Control Systems's headquarters?
Vascular Control Systems's headquarters is located at 32236 Paseo Adelanto, San Juan Capistrano.
What is Vascular Control Systems's latest funding round?
Vascular Control Systems's latest funding round is Acquired.
How much did Vascular Control Systems raise?
Vascular Control Systems raised a total of $5.75M.
Who are the investors of Vascular Control Systems?
Investors of Vascular Control Systems include Ethicon and MedVenture Associates.
Who are Vascular Control Systems's competitors?
Competitors of Vascular Control Systems include Sequent Medical, Veryan Medical, arstasis, Pioneer Surgical Technology, Bio Control Medical and 11 more.
Compare Vascular Control Systems to Competitors
Novare Surgical Systems, Inc. develops atraumatic systems that aim to provide surgeons with unmatched confidence in and control of their surgical occlusion. With its engineered designs, the company aims to expand the surgical temporary occlusion markets of the U.S. and Europe, estimated to be worth up to $155 million each.
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Mpathy Medical has developed a range of less invasive surgical solutions to restore pelvic health to women. The company's responsive team aims to provide a relationship with the individuals who really matter, women and their surgeons.
REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.
Tayside Flow Technologies Limited is a medical device company. It had developed the Spiral Laminar Flow Vascular Arteriovenous Graft.Tayside Flow Technologies Ltd (TFT) is a medical technology company focussed on the development of cardiovascular devices based on a new understanding of blood flow dynamics, Spiral Laminar Flow.
Devices for Vascular Interventions offers atherectomy systems for removal of plaque from coronary arteries
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.